We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Kristen Harrison, MPH
Advertisement
Articles by Kristen Harrison, MPH
With new drugs in the pipeline and the impact of updated FDA drug safety policies on colchicine, gout may no longer be inexpensive to treat.
Advertisement
Latest Updated Articles
- Trends in Medication Utilization and the Cost of Treatment for Gout
Published: June 7th 2013 | Updated:
- The Expanding Role of New Medications in the Treatment of Type 2 Diabetes Mellitus
Published: August 21st 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
5
